OPEN ACCESS Freely available online

ISSN: 2161-0509
Journal of Nutritional Disorders & Therapy

Short Communication

# Abetalipoproteinemia: Understanding a Rare Disorder of Fat Transport and Nutrition

**Emily Chadler***

*Department of Molecular Medicine, Westbridge University, Manchester, United Kingdom*

## DESCRIPTION

Abetalipoproteinemia is an uncommon inherited metabolic disorder that affects the body's ability to absorb and transport dietary fats. The condition results from mutations in the gene, which plays an important role in the formation of lipoproteins containing apolipoprotein B. Without normal lipoprotein production, fats and fat-soluble vitamins cannot be efficiently transported through the bloodstream, leading to a wide range of nutritional, neurological, gastrointestinal, and ophthalmological complications. Although the disorder is rare, its effects can be severe if diagnosis and treatment are delayed [1].

The condition is inherited in an autosomal recessive manner, meaning that an affected individual receives a defective copy of the gene from both parents. Parents who carry a single altered copy usually do not show symptoms. Because of its rarity, many healthcare providers may encounter only a few cases during their careers. Nevertheless, awareness of the disorder remains important because early intervention can significantly improve long-term outcomes [2].

One of the earliest signs of abetalipoproteinemia appears during infancy. Affected children often experience poor growth, chronic diarrhea, vomiting, and difficulties gaining weight despite adequate food intake. These symptoms occur because fats consumed in the diet are not properly absorbed in the intestine. Instead of entering circulation, fats accumulate within intestinal cells, interfering with normal digestive processes. As a result, stools may become bulky, pale, and greasy, a condition commonly referred to as steatorrhea [3-4].

The inability to absorb dietary fats also limits the absorption of vitamins A, D, E, and K. These vitamins require fat for intestinal uptake. Deficiencies may gradually develop and contribute to many of the clinical manifestations observed in patients. Among these deficiencies, vitamin E deficiency is particularly important because it can lead to progressive neurological damage [5-8]. Early diagnosis and consistent vitamin supplementation are essential to prevent long-term complications.

Improved diagnostic methods may enable earlier identification of affected individuals, particularly in families with a known history of the disorder. Earlier diagnosis can reduce the risk of irreversible complications, especially neurological and visual impairment [9].

Treatment of abetalipoproteinemia primarily focuses on improving nutrition, correcting vitamin deficiencies, and preventing long-term complications. Patients are generally advised to follow a low-fat diet while maintaining adequate calories and essential fatty acids for healthy growth and development. High-dose supplementation of fat-soluble vitamins, particularly vitamins A, D, E, and K, is essential because their absorption is impaired. Vitamin E is especially important for reducing the risk of neurological complications. Regular monitoring of nutritional status, liver function, vision, and neurological health helps guide treatment. Early and continuous management can improve growth, reduce symptoms, and support better long-term health outcomes.

Long-term treatment also requires regular follow-up with healthcare professionals to monitor vitamin levels, growth, and possible complications. Supplementation should be carefully adjusted according to individual needs. Essential fatty acids may be included in controlled amounts, while dietary counseling helps maintain balanced nutrition and prevent excessive fat intake that can worsen gastrointestinal symptoms.

Care for individuals with abetalipoproteinemia involves lifelong nutritional support, regular medical checkups, and monitoring for neurological, vision, and gastrointestinal problems. Families should follow prescribed diets and vitamin supplementation consistently. Maintaining healthy growth, preventing deficiencies, and recognizing new symptoms early are important. Regular communication with healthcare professionals helps ensure effective, individualized care. Genetic counseling and ongoing follow-up can also help families understand the condition, manage complications, and improve long-term quality of life.

**Correspondence to:** Emily Chadler, Department of Molecular Medicine, Westbridge University, Manchester, United Kingdom, E-mail: emily.c.research@mm-ac.uk

**Received:** 25-May-2026, Manuscript No. JNDT-26-32147; **Editor assigned:** 27-May-2026, PreQC No. JNDT-26-32147 (PQ); **Reviewed:** 10-Jun-2026, QC No. JNDT-26-32147; **Revised:** 14-Jun-2026, Manuscript No. JNDT-26-32147 (R); **Published:** 24-Jun-2026, DOI: 10.35248/2161-0509.26.16.365.

**Citation:** Chadler E (2026). Abetalipoproteinemia: Understanding a Rare Disorder of Fat Transport and Nutrition. J Nutr Disord Ther. 16:365.

**Copyright:** © 2026 Chadler E. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.

## CONCLUSION

Although abetalipoproteinemia remains a rare condition, its clinical significance extends beyond the small number of affected individuals. The disorder illustrates the essential role of lipid transport systems in human physiology and highlights the relationship between nutrition, genetics, and health [10]. Recognition of symptoms, timely diagnosis, and comprehensive nutritional management can substantially improve outcomes. Continued scientific investigation and clinical awareness will contribute to better care for patients and a deeper understanding of the complex processes involved in fat metabolism and nutrient absorption. Advances in molecular genetics continue to improve understanding of disease mechanisms. Researchers are investigating how different mutations influence symptom severity and treatment responses.

## REFERENCES

1. Takahashi M, Okazaki H, Ohashi K, Ogura M, Ishibashi S, Okazaki S, et al. Current diagnosis and management of abetalipoproteinemia. J Atheroscler Thromb. 2021;28(10): 1009-1019.
2. Zamel R, Khan R, Pollex RL, Hegele RA. Abetalipoproteinemia: Two case reports and literature review. Orphanet J Rare Dis. 2008;3(1):19.
3. Sharp D, Blinderman L, Combs KA, Kienzle B, Ricci B, Wager-Smith K, et al. Cloning and gene defects in microsomal triglyceride transfer protein associated with abetalipoproteinaemia. Nature. 1993;365(6441):65-69.
4. Bassen FA, Kornzweig AL. Malformation of the erythrocytes in a case of atypical retinitis pigmentosa. Blood. 1950;5(4):381-387.
5. Vlasschaert C, McIntyre AD, Thomson LA, Kennedy BA, Ratko S, Prasad C, et al. Abetalipoproteinemia due to a novel splicing variant in MTTP in 3 siblings. J Investig Med High Impact Case Rep. 2021;9:23247096211022484.
6. Levy RI, Fredrickson DS, Laster L. The lipoproteins and lipid transport in abetalipoproteinemia. J Clin Invest. 1966;45(4):531-541.
7. Gregg RE, Wetterau JR. The molecular basis of abetalipoproteinemia. Curr Opin Lipidol. 1994;5(2):81-86.
8. Scanu AM, Aggerbeck LP, Kruski AW, Lim CT, Kayden HJ. A study of the abnormal lipoproteins in abetalipoproteinemia. J Clin Invest. 1974;53(2):440-453.
9. Bredefeld C, Peretti N, Hussain MM, Di Filippo M, Granot E, Cuerq C, et al. New classification and management of abetalipoproteinemia and related disorders. Gastroenterology. 2021;160(6):1912-1916.
10. Alaupovic P. The role of apolipoproteins in lipid transport processes. Ric Clin Lab 1982;12(1):3-21.